Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Investments: 2020-2024

Historic Long-Term Investments for Amphastar Pharmaceuticals (AMPH) over the last 5 years, with Dec 2024 value amounting to $11.0 million.

  • Amphastar Pharmaceuticals' Long-Term Investments rose 41.49% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 million, marking a year-over-year increase of 41.49%. This contributed to the annual value of $11.0 million for FY2024, which is 25.12% down from last year.
  • Amphastar Pharmaceuticals' Long-Term Investments amounted to $11.0 million in FY2024, which was down 25.12% from $14.7 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Long-Term Investments' 5-year high stood at $14.7 million during FY2023, with a 5-year trough of $1.6 million in FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' Long-Term Investments averaged around $10.1 million, with its median value being $11.0 million (2024).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Long-Term Investments surged by 226.33% in 2023, and later decreased by 25.12% in 2024.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Long-Term Investments stood at $1.6 million in 2020, then soared by 149.06% to $4.0 million in 2021, then grew by 12.92% to $4.5 million in 2022, then surged by 226.33% to $14.7 million in 2023, then fell by 25.12% to $11.0 million in 2024.